NewsRoom Articles - BioMedWire (BMW)

FridayDec 05, 2025 10:00 am

Nasal Drops Hold Promise in Fighting Deadly Brain Cancer

The fight against glioblastoma, a deadly brain cancer, has been boosted by new research conducted at Washington University that has developed nasal drops which can travel through nerves found in the nose and reach different parts of our central nervous system in order to fight the glioblastoma cells there. Preliminary results revealed that this novel medication safely reached the intended target and protected the mice against the fatal tumors. Alexander Stegh, a neurosurgeon at the university, explains that their approach offers hope for more effective and safer treatments for this deadliest brain cancer and possibly other cancers that are resistant…

ThursdayDec 04, 2025 10:00 am

Cancer Immunotherapy Could Be Boosted by Targeting Pathways of DNA Repair

A newly published study shows that the fight against cancer could be boosted by considering approaches that seek to disrupt the mechanisms through which tumor cells respond to damage to their DNA. Targeting these pathways could make immunotherapy more effective for a lot more people. The study team led by Tang Z. focused on DDR (DNA Damage Response), a process at the cellular level in which cells undertake a variety of measures to fix any damage to their DNA. This repair process is intended to keep the tumor functioning and able to continue growing and spreading. By disrupting DDR, cancer…

ThursdayDec 04, 2025 9:00 am

Breakthrough Therapies Advance as Rare Disease Burden Intensifies Across Aging Populations

BioMedWire Editorial Coverage: Chronic illnesses and rare disorders among older Americans represent a rapidly intensifying challenge for the U.S. healthcare system, with the National Institutes of Health estimating that more than 30 million people nationwide are living with a rare disease. Most of these conditions have no FDA-approved therapies, leaving older adults particularly at risk as age-related changes can mask or delay accurate diagnosis. This growing strain on care has heightened the need for novel treatments that address significant unmet medical needs. Soligenix Inc. (NASDAQ: SNGX) (profile), a late-stage biopharmaceutical developer, is advancing several rare-disease therapies, including HyBryte[TM] (synthetic hypericin)…

TuesdayDec 02, 2025 10:00 am

Could Copying Lessons from Europe Help America Fix its Healthcare System?

The steep cost of healthcare in the U.S. has always been, and is becoming an even bigger political issue with each passing year. The issue was at the center of the recent shutdown of the federal government and the shutdown was only ended after a promise that the expiring healthcare subsidies would be voted on this month. Health insurance costs are soaring while citizens grapple with a high cost of living. According to a report published by the OECD last month, the per capita expenditure on healthcare in the U.S. far exceeds the per capita cost in other countries. Despite…

TuesdayDec 02, 2025 9:00 am

Chronic Rare Diseases in an Aging America: Why HyBryte and Federal Policy Matter Now

BioMedWire Editorial Coverage: Chronic conditions and rare diseases in the aging population present an urgent and expanding challenge within the U.S. healthcare system, especially as more than 30 million Americans are affected by rare diseases, according to the National Institutes of Health. The vast majority of these conditions lack any FDA-approved treatment, leaving older adults especially vulnerable as age-related symptoms often obscure or delay diagnosis. This rising burden has increased demand for new therapies that can address real unmet need. Soligenix Inc. (NASDAQ: SNGX) (Profile), a late-stage biopharmaceutical company, is developing multiple treatments for rare diseases, including HyBryte[TM] (synthetic hypericin)…

MondayDec 01, 2025 1:15 pm

Soligenix Inc. (NASDAQ: SNGX) Reaches Key Enrollment Milestone in Phase 3 Trial with Encouraging Blinded Response Rate

The enrollment milestone represents a crucial step forward for the FLASH2 study, which builds upon the previous statistically significant Phase 3 FLASH study. The promising early results are further corroborated by an ongoing investigator-initiated study being conducted at the University of Pennsylvania. Soligenix is positioning itself to potentially deliver the first FDA-approved photodynamic therapy specifically indicated for CTCL. In a pivotal advancement for patients suffering from a rare form of skin cancer, Soligenix (NASDAQ: SNGX) has achieved a critical clinical trial milestone that brings its investigational treatment significantly closer to potential FDA approval. The company announced that is has completed the planned…

MondayDec 01, 2025 10:00 am

Study Uncovers Surprising Connection Between Choline, Obesity and Brain Inflammation

For a long time, the scientific community has known that anything that causes harm to the body usually also harms our brains. Conditions like insulin resistance, obesity and high blood pressure strain the body’s metabolic and vascular systems. With time, this stress accelerates cognitive decline and amplifies Alzheimer’s risk. Now, a new study conducted by a team at Arizona State University (ASU) together with collaborators elsewhere has shown that the harmful effects often start much earlier than had initially been thought. They observed that obese young adults exhibited a pattern of subtle changes suggesting early brain damage. These same patterns…

TuesdayNov 25, 2025 10:30 am

Soligenix Inc. (NASDAQ: SNGX) Elevates Advisory Network as Rare Disease Strategy Advances

Philipson will serve as a strategic advisor to Soligenix, contributing extensive expertise in U.S. economic policy, healthcare regulation and corporate strategy. The significance of this appointment lies in the convergence of science, healthcare regulation and policy economics. The addition of Philipson complements the company’s mission to develop and commercialize products to treat rare diseases where there is an unmet medical need. Soligenix (NASDAQ: SNGX) is entering a new phase of strategic breadth and influence with the appointment of a seasoned, high-level scientific and policy adviser who brings rarefied experience at the intersection of economics, government and healthcare innovation. The company,…

TuesdayNov 25, 2025 10:00 am

Common Drug for Blood Pressure Could Slow Glioblastoma

Researchers studying how a common drug, hydralazine, for blood pressure and preeclampsia works at the cellular level have identified the specific mechanism through which it works and their discovery has revealed that the medication that has been around for more than half a century could find new application as a way to slow down how aggressively glioblastoma grows. Despite how long this drug has been in use, it wasn’t clear how exactly it attained the effects it has upon blood pressure. This isn’t unique to hydralazine, as only 10-20% of all existing medications have known mechanisms of action. In a…

MondayNov 24, 2025 10:30 am

Soligenix Inc. (NASDAQ: SNGX) Strengthens CTCL Program as DMC Flags No Safety Issues

This milestone is significant because regulatory pathways for orphan diseases such as CTCL often hinge not only on efficacy, but on establishing a favorable safety profile. Soligenix’s announcement arrives amid mounting interest in HyBryte[TM] as a novel skin-directed therapy. For biotechnology companies working in rare diseases, reaching a safety milestone means one major hurdle is cleared and focus can shift more explicitly to efficacy and regulatory strategy. In a key development that underscores the advancing clinical trajectory of its lead therapy, Soligenix (NASDAQ: SNGX) announced that the Data Monitoring Committee (“DMC”) overseeing its confirmatory Phase 3 FLASH2 trial of HyBryte(TM)…

News and publishing service for medical and biotechnology related companies

Contact us: 512.354.7000

Nasal Drops Hold Promise in Fighting Deadly Brain Cancer

Cancer Immunotherapy Could Be Boosted by Targeting Pathways of DNA Repair

Breakthrough Therapies Advance as Rare Disease Burden Intensifies Across Aging Populations

Could Copying Lessons from Europe Help America Fix its Healthcare System?

Chronic Rare Diseases in an Aging America: Why HyBryte and Federal Policy Matter Now

Soligenix Inc. (NASDAQ: SNGX) Reaches Key Enrollment Milestone in Phase 3 Trial with Encouraging Blinded Response Rate

Study Uncovers Surprising Connection Between Choline, Obesity and Brain Inflammation

Soligenix Inc. (NASDAQ: SNGX) Elevates Advisory Network as Rare Disease Strategy Advances

Common Drug for Blood Pressure Could Slow Glioblastoma

Soligenix Inc. (NASDAQ: SNGX) Strengthens CTCL Program as DMC Flags No Safety Issues

Official NewsWire Relationships

BioMedWire Currently Accepts

BioMedWire

Company Search

Site Search